Immunovant, Inc. IMVT Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Immunovant, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s return on equity?
- Immunovant, Inc. (IMVT) reported return on equity of -64.8% in Q1 2026.
- How has Immunovant, Inc.'s return on equity changed year-over-year?
- Immunovant, Inc.'s return on equity decreased by 3.8% year-over-year, from -62.5% to -64.8%.
- What is the long-term trend for Immunovant, Inc.'s return on equity?
- Over 5 years (2021 to 2026), Immunovant, Inc.'s return on equity has grown at a 7.9% compound annual growth rate (CAGR), from -44.3% to -64.8%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.